Lamberto Andreotti joined EW as Senior Advisor in 2017. Mr. Andreotti has a long and successful career as a senior executive in the pharmaceutical industry. Mr. Andreotti retired in 2017 as Chairman of Bristol Myers Squibb (BMS), one of the largest global pharmaceutical companies, with annual revenues of approximately $20 billion and market capitalization of approximately $100 billion.
Mr. Andreotti first joined BMS in 1998 as Vice President and General Manager of European Oncology and Italy, and advanced to President, Europe in 2000, President, International in 2002 and President, Pharmaceuticals in 2005. He became Chief Operating Officer in 2008 and was elected to the Board of Directors the following year. He was appointed CEO in 2010, and ultimately appointed Chairman of the Board in 2015.
Under Mr. Andreotti’s leadership, Bristol-Myers Squibb transformed into a leader in the biopharma industry and pioneered the field of immuno-oncology. The company was the first to market with immuno-oncology medicines for metastatic melanoma and lung cancer - two of the most common and deadly diseases - which have revolutionized the treatment of many cancers. He was also credited with leading the company in enhancing the value of the company’s pipeline, negotiating valuable partnerships with other major pharmaceutical companies and achieving excellent shareholder returns.
Before joining BMS, Mr. Andreotti held the positions of Senior Corporate Vice President and President of Oncology at Pharmacia & Upjohn, and served in various senior roles at Recordati, Farmitalia Carlo Erba, Pharmacia and Pharmacia & Upjohn.
Mr. Andreotti is a Board member of Corteva Agriscience (ex-Dupont and DowDupont) and UniCredit. He also serves as a director for the American Italian Cancer Foundation and the Salzburg Festival Society.
Originally from Rome, Italy, Mr. Andreotti received his Bachelor’s degree in Engineering from Università La Sapienza of Rome and his Master of Science degree from the Massachusetts Institute of Technology.